{"denoms":[{"counts":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"52"}],"units":"Participants"}],"groups":[{"description":"Patients with baseline platelet counts \\>50,000 k/uL received lenalidomide (LEN) PO daily or QOD on days 1-21. If platelet counts fell below 50,000 k/uL during treatment, patients discontinued LEN and received eltrombopag olamine (ELT) PO daily or QOD until platelet counts \\> 50,000 k/uL were achieved, and then maintained for 2 weeks thereafter. If a platelet count \\>50,000 k/uL was maintained, patients discontinued ELT and resumed only LEN as a single agent (PO daily or QOD). If platelets fell below 50,000 k/uL a second time, LEN was stopped and ELT was re-initiated at the dose last given to the patient. Once platelet counts were \\>50,000 k/uL and maintained for 2 weeks, patients resumed LEN concurrently with ELT for all subsequent courses.\n\nTreatment repeated every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.\n\nEltrombopag Olamine: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO","id":"BG000","title":"Arm A (Platelets > 50,000 k/uL) LEN Initiation"},{"description":"Patients with baseline platelet counts \\<50,000 k/uL received eltrombopag olamine (ELT) PO daily or QOD on days 1-28 until a platelet count \\>50,000 k/uL was achieved. Once a platelet count\\>50,000 k/uL was achieved the ELT dose was maintained for two weeks. After two weeks ELT was discontinued and LEN was started as in Arm A (i.e., eltrombopag olamine discontinued and lenalidomide started). Patients in Arm B were permitted to stay on ELT alone if a hematologic response on ELT was achieved as defined by the 2006 International Working Group (IWG) consensus criteria, or if baseline hemoglobin was \\>10.0 g/dL and didn't decrease while on study drug.\n\nTreatment repeated every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.\n\nEltrombopag Olamine: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO","id":"BG001","title":"Arm B (Platelets < 50,000 k/uL) ELT Initiation With Potential LEN Combination"},{"description":"Patients in Arm B were permitted to stay on ELT alone if a hematologic response on ELT was achieved as defined by the 2006 International Working Group (IWG) consensus criteria, or if baseline hemoglobin was \\>10.0 g/dL and didn't decrease while on study drug.\n\nTreatment repeated every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.\n\nEltrombopag Olamine: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies","id":"BG002","title":"Arm C (Platelets < 50,000 k/uL) ELT Monotherapy"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"59","upperLimit":"86","value":"74"},{"groupId":"BG001","lowerLimit":"56","upperLimit":"85","value":"73"},{"groupId":"BG002","lowerLimit":"34","upperLimit":"93","value":"68"},{"groupId":"BG003","lowerLimit":"34","upperLimit":"93","value":"71"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"15"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"37"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"29"}]}],"title":"Non-Hispanic White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"9"}]}],"title":"Non-Hispanic Black"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"11"}]}],"title":"Hispanic"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}]}],"title":"Unknown (Not Documented)"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"52"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"6.2","upperLimit":"9.5","value":"8.2"},{"groupId":"BG001","lowerLimit":"6.4","upperLimit":"10.8","value":"8.1"},{"groupId":"BG002","lowerLimit":"6.1","upperLimit":"11.7","value":"8.6"},{"groupId":"BG003","lowerLimit":"6.1","upperLimit":"11.7","value":"8.4"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEAN","title":"Baseline Hemoglobin","unitOfMeasure":"g/dL"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"88","upperLimit":"457","value":"257"},{"groupId":"BG001","lowerLimit":"16","upperLimit":"280","value":"134"},{"groupId":"BG002","lowerLimit":"1","upperLimit":"97","value":"19"},{"groupId":"BG003","lowerLimit":"1","upperLimit":"457","value":"126"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEAN","title":"Baseline Platelet","unitOfMeasure":"platelets x10^9/L"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0","upperLimit":"5","value":"1.96"},{"groupId":"BG001","lowerLimit":"0","upperLimit":"6","value":"1.87"},{"groupId":"BG002","lowerLimit":"0","upperLimit":"8","value":"1.8"},{"groupId":"BG003","lowerLimit":"0","upperLimit":"8","value":"1.87"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEAN","title":"Blast Count","unitOfMeasure":"percentage of blasts in bone marrow cell"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"19"},{"groupId":"BG003","value":"49"}]}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Myelodysplastic Syndrome (MDS)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"3"}]}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Chronic Myelomonocytic Leukemia (CMML)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}],"title":"Very Low Risk"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"24"}],"title":"Low Risk"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"27"}],"title":"Intermediate Risk"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndrome (MDS)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0","upperLimit":"3","value":"0.63"},{"groupId":"BG001","lowerLimit":"0","upperLimit":"2","value":"0.53"},{"groupId":"BG002","lowerLimit":"0","upperLimit":"3","value":"0.48"},{"groupId":"BG003","lowerLimit":"0","upperLimit":"3","value":"0.54"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEAN","title":"Number of Prior Treatments","unitOfMeasure":"Prior Treatments"}]}